Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

SNSS 0.910 +0.029 (3.26%)
price chart
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Analyst Price Target
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): 3 analysts have set the short term price target of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) at $1.83. The standard deviation of short term price target has been estimated at $0.29, implying that the ...
Sunesis Pharmaceuticals Cut to "Hold" at Zacks (SNSS)  WKRB News
Sunesis Pharmaceuticals Receives Average Rating of "Hold" from Brokerages ...
Zacks upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Wednesday, September 30th. Wedbush set a $2.00 price target on Sunesis Pharmaceuticals and gave the stock a “hold” ...
Morning Watch List: Bank of America Corporation (NYSE:BAC), Sunesis ...
In recognition of the United Nations' World Habitat Day, Bank of America Corporation (NYSE:BAC), in partnership with Habitat for Humanity International, is launching its second Global Build, taking place in eight countries around the world.
Company Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Drops by -15.75%
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has lost 15.75% during the past week and dropped 20.22% in the last 4 weeks.
GPM Announces Investigation of Sunesis Pharmaceuticals, Inc.
LOS ANGELES, Jul 27, 2015 (BUSINESS WIRE) -- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") SNSS, -5.41% The investigation concerns whether the ...
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5%
Sunesis Pharmaceuticals Inc (SNSS) Files Form 4 Insider Selling : Steven B ...  Insider Trading Report
Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) has been on the move lately as the stock has risen by 27.6% in the past four weeks, and it is currently trading well above its 20-Day SMA.
FDA seeks more clinical evidence on Sunesis Pharma cancer drug
Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company's shares down 60 percent in after-market trading.
Is This the End of Sunesis?  24/7 Wall St.
Sunesis Pharmaceuticals Announces Regulatory Update  GlobeNewswire (press release)
Sunesis Pharmaceuticals, Inc. Short Interest Update
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has shown a drop of 15.5% or 545,122 shares in the short positions. The bets have increased to 2,961,778 shares on September 15,2015 from 3,506,900 shares on August 31,2015.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Price Target Update
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): The mean estimate for the short term price target for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) stands at $2.13 according to 4 Analysts. The higher price target estimate for the stock has been calculated ...
Company Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Rally 3.42%
Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rose by 3.42% in the past week and 6.14% for the last 4 weeks.
Brokerages Set Sunesis Pharmaceuticals Target Price at $2.70 (NASDAQ:SNSS)  Financial Wisdom Works
Biotech Stocks: Here's Where to Get In- ACADIA Pharmaceuticals Inc ...  Wall Street Point